- Home
- MDT vs SNY Comparison
MDT vs SNY Comparison
Compare MDT & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDT
- SNY
- Stock Information
- Founded
- MDT 1949
- SNY 1994
- Country
- MDT Ireland
- SNY France
- Employees
- MDT N/A
- SNY N/A
- Industry
- MDT Biotechnology: Electromedical & Electrotherapeutic Apparatus
- SNY Biotechnology: Pharmaceutical Preparations
- Sector
- MDT Health Care
- SNY Health Care
- Exchange
- MDT Nasdaq
- SNY Nasdaq
- Market Cap
- MDT 114.9B
- SNY 116.1B
- IPO Year
- MDT N/A
- SNY N/A
- Fundamental
- Price
- MDT $93.87
- SNY $51.00
- Analyst Decision
- MDT Buy
- SNY Buy
- Analyst Count
- MDT 16
- SNY 4
- Target Price
- MDT $104.07
- SNY $61.50
- AVG Volume (30 Days)
- MDT 6.5M
- SNY 3.1M
- Earning Date
- MDT 11-18-2025
- SNY 10-24-2025
- Dividend Yield
- MDT 3.03%
- SNY 3.11%
- EPS Growth
- MDT 21.95
- SNY 105.93
- EPS
- MDT 3.62
- SNY 8.67
- Revenue
- MDT $34,200,000,000.00
- SNY $53,890,648,839.00
- Revenue This Year
- MDT $7.97
- SNY $1.40
- Revenue Next Year
- MDT $5.47
- SNY $6.67
- P/E Ratio
- MDT $26.00
- SNY $11.67
- Revenue Growth
- MDT 4.98
- SNY N/A
- 52 Week Low
- MDT $79.29
- SNY $44.62
- 52 Week High
- MDT $99.37
- SNY $60.12
- Technical
- Relative Strength Index (RSI)
- MDT 43.40
- SNY 59.74
- Support Level
- MDT $93.11
- SNY $49.62
- Resistance Level
- MDT $97.24
- SNY $52.20
- Average True Range (ATR)
- MDT 1.67
- SNY 0.66
- MACD
- MDT -0.40
- SNY 0.19
- Stochastic Oscillator
- MDT 31.42
- SNY 72.42
About MDT Medtronic plc.
One of the largest medical-device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, transcatheter heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, ablation laser therapy, and surgical tools. The company primarily markets its products to healthcare institutions and physicians in the United States, Western Europe, and Japan. Foreign sales account for roughly 50% of the company's total sales.
About SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.